Brevan Howard Capital Management’s Charles River Laboratories CRL Stock Holding History

Brevan Howard Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$864K	Sell	3,808 -1,904	-33%	-$339K	0.01%	1150
2026 Q1	$985K	Buy	+5,712	New	+$1.06M	0.01%	906
2025 Q4	–	Sell	-11,197	Closed	-$1.75M	–	1885
2025 Q3	$1.75M	Sell	11,197 -22,347	-67%	-$3.55M	0.01%	623
2025 Q2	$5.09M	Buy	33,544 +28,015	+507%	+$3.74M	0.03%	364
2025 Q1	$832K	Sell	5,529 -2,479	-31%	-$416K	0.01%	562
2024 Q4	$1.48M	Buy	8,008 +3,794	+90%	+$731K	0.01%	344
2024 Q3	$830K	Buy	4,214 +1,465	+53%	+$304K	0.01%	512
2024 Q2	$568K	Buy	+2,749	New	+$623K	0.01%	560

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Brevan Howard Capital Management's CRL Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its Charles River Laboratories (CRL) stake by 33% in Q2 2026, selling an estimated $339K and leaving 3,808 shares worth $864K. The position accounts for 0.01% of the portfolio, ranked #1150.

Brevan Howard Capital Management first reported a position in CRL in Q2 2024 and has held it in 8 quarters since. The position peaked at $5.09M in Q2 2025. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Brevan Howard Capital Management held 3,808 shares of Charles River Laboratories worth $864K as of Q2 2026.
Brevan Howard Capital Management sold 1,904 Charles River Laboratories shares in Q2 2026, an estimated $339K.
Charles River Laboratories made up 0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1150 holding.
Brevan Howard Capital Management first reported a position in Charles River Laboratories in Q2 2024 and has held it in 8 quarters since.
Brevan Howard Capital Management's Charles River Laboratories position peaked at $5.09M in Q2 2025.
568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.